CALC
CalciMedica, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-1410.72
P/S
0.00
EV/EBITDA
-0.36
DCF Value
$0.00
FCF Yield
-215.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-1172.9%
ROA
-217.5%
ROIC
-209.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-10.8M | $-0.70 |
| FY 2025 | $0.00 | $-29.6M | $-1.97 |
| Q3 2025 | $0.00 | $-7.8M | $-0.52 |
| Q2 2025 | $0.00 | $-6.0M | $-0.40 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$266.00
Target (Median)
$392.00
Target Range
$14.00 - $392.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.09
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.